切换导航
关闭
  • 菜单
  • Setting

Tyrosine Kinase - Colorectal Cancer

Tyrosine kinase is a large group of proteins regulates the function of cell growth, differentiation, motility, cytoskeletal rearrangement and adhesion etc. They activate the target protein through transfer of phosphate from ATP to the hydroxyl group of a target protein tyrosine. Transmembrane receptor kinases and non-receptor cytoplasmic kinases are two main categories of the tyrosine kinases.

Receptor tyrosine kinases bind to extracellular ligands/growth factors, which promotes receptor dimerization and autophosphorylation of receptor tyrosine residues. This triggers a cascade of downstream events through phosphorylation of intracellular proteins that ultimately transduce the extracellular signal to the nucleus, causing changes in gene expression. Receptor tyrosine kinases include EGFR/ErbB, PDGFR, VEGFR, FGFR and MET subfamilies etc. Dysfunctions in tyrosine phosphorylation are linked to oncogenic transformation. In additions, various adaptor and effector proteins couple to carboxy-terminal of an active kinase. For instance, binding of the GRB2 adaptor protein activates EGFR and MAPK/ERK signaling.

Non-receptor tyrosine kinases involve many well-defined proteins (e.g. the Src family kinases, c-Abl, and Jak kinases) and other kinases which regulates cell growth and differentiation. For example, Src family kinases are curial for activating and inhibitory pathways in the innate immune response.

12件产品中的 1-10

页面
每页
清除全部
  1. Entrectinib
    B5859 Entrectinib
    中文名: 恩曲替尼
    Target: Trk Receptors|ALK|ROS1
    Summary: ALK激酶抑制剂
      ≥28.05 mg/mL
      insoluble in H2O
  2. AZD2932
    B5835 AZD2932
    Target: FLT3|VEGFR|PDGFR|c-Kit
    Summary: VEGFR-2\PDGFRβ\Flt-3和c-Kit的抑制剂
      Soluble in DMSO
  3. Axitinib (AG 013736)
    A8370 Axitinib (AG 013736)
     1 Citation
    中文名: 阿西替尼
    Target: VEGFR|PDGFR|c-Kit
    Summary: VEGFR1/ c-Kit抑制剂
      ≥19.3 mg/mL
      insoluble in H2O
  4. Tivantinib (ARQ 197)
    A8325 Tivantinib (ARQ 197)
     2 Citation
    Target: MET
    Summary: C-Met抑制剂
      ≥18.47 mg/mL
      ≥2.29 mg/mL
  5. Cediranib (AZD217)
    A1882 Cediranib (AZD217)
    中文名: 西地尼布
    Target: VEGFR
    Summary: VEGFR受体高度有效的抑制剂
      ≥22.52 mg/mL
      insoluble in H2O
  6. Dovitinib (TKI-258, CHIR-258)
    A2168 Dovitinib (TKI-258, CHIR-258)
     2 Citation
    中文名: 多韦替尼
    Target: FLT3|VEGFR|PDGFR|c-Kit|FGFR
    Summary: 多靶点RTK抑制剂
      ≥36.35 mg/mL
      insoluble in H2O
  7. Nintedanib (BIBF 1120)
    A8252 Nintedanib (BIBF 1120)
     3 Citation
    中文名: 尼达尼布
    Target: VEGFR|PDGFR|FGFR
    Summary: VEGFR/PDGFR/FGFR抑制剂
      ≥5.34 mg/mL
      insoluble in H2O
  8. Sorafenib Tosylate
    A8245 Sorafenib Tosylate
     1 Citation
    中文名: 甲苯磺酸索拉非尼
    Target: Raf|VEGFR
    Summary: Raf激酶和酪氨酸激酶抑制剂
      ≥31.85 mg/mL
      insoluble in H2O
  9. Regorafenib
    A8236 Regorafenib
     4 Citation
    中文名: 瑞戈非尼
    Target: Raf|VEGFR|PDGFR|c-Kit|RET
    Summary: VEGFR/PDGFR/FGFR/mutant Kit/RET/Raf-1抑制剂
      ≥25.04 mg/mL
      insoluble in H2O
  10. Gefitinib (ZD1839)
    A8219 Gefitinib (ZD1839)
     3 Citation
    中文名: 吉非替尼
    Target: EGFR
    Summary: EGFR抑制剂
      ≥22.34 mg/mL
      insoluble in H2O

12件产品中的 1-10

页面
每页